Global Health Limited (ASX: GLH) reported stronger operating momentum in its June 2026 quarterly update, supported by higher customer receipts and continued progress in its software transformation. Customer receipts for the 12 months to June 2026 increased 12.6% year on year to AU$9.53 million, while operating and investing cash outflows declined by 30%, reflecting improved cost efficiency. The company also expects lower research and development expenditure and additional savings from wider AI adoption across its operations.
During the quarter, Global Health completed key technology upgrades, integrated AI capabilities into its healthcare platforms, and expanded deployments of its MasterCare Plus SaaS solution. Management indicated that the company will now prioritise revenue growth following several years of platform investment, with international expansion and AI-driven products expected to support future growth. The company also achieved positive cash-basis EBITDA in both the March and June quarters and aims to maintain profitable operations and positive cash flow through FY2027.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
ASX: GLH Reports Higher Customer Receipts and Advances SaaS, AI-Led Growth Strategy
Global Health Limited (ASX: GLH) reported stronger operating momentum in its June 2026 quarterly update, supported by higher customer receipts and continued progress in its software transformation. Customer receipts for the 12 months to June 2026 increased 12.6% year on year to AU$9.53 million, while operating and investing cash outflows declined by 30%, reflecting improved cost efficiency. The company also expects lower research and development expenditure and additional savings from wider AI adoption across its operations.
During the quarter, Global Health completed key technology upgrades, integrated AI capabilities into its healthcare platforms, and expanded deployments of its MasterCare Plus SaaS solution. Management indicated that the company will now prioritise revenue growth following several years of platform investment, with international expansion and AI-driven products expected to support future growth. The company also achieved positive cash-basis EBITDA in both the March and June quarters and aims to maintain profitable operations and positive cash flow through FY2027.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au